OSE Immunotherapeutics SA
PAR:OSE
OSE Immunotherapeutics SA
Total Equity
OSE Immunotherapeutics SA
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Total Equity
€63.8m
|
CAGR 3-Years
10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Equity
€181.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Equity
€97.4m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Inventiva SA
PAR:IVA
|
Total Equity
-€106.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Equity
$79.2m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
10%
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Total Equity
€178.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
41%
|
CAGR 10-Years
24%
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Total Equity?
Total Equity
63.8m
EUR
Based on the financial report for Dec 31, 2024, OSE Immunotherapeutics SA's Total Equity amounts to 63.8m EUR.
What is OSE Immunotherapeutics SA's Total Equity growth rate?
Total Equity CAGR 5Y
2%
Over the last year, the Total Equity growth was 178%. The average annual Total Equity growth rates for OSE Immunotherapeutics SA have been 10% over the past three years , 2% over the past five years .
You don't have any saved screeners yet